

07 MAR 2005

PC 03/00742



IL03/00742

מדינת ישראל
STATE OF ISRAEL

REC'D 14 9GT 2003	
WIPO	PCT

Ministry of Justice
Patent Office

משרד המשפטים
לשכת הפטנטים

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
of which particulars are
specified on the first page
of the annex.

זאת לתעודה כי
רצופים בזה העתקים
נכונים של המסמכים
שהופקדו לכתחילה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)



This 10-09-2003
היום
רשם הפטנטים
Commissioner of Patents

נתאשר
Certified

BEST AVAILABLE COPY

לשימוש הלשכה
For Office Use

13382/mic/01

בקשה לפטנט
Application for Patent

מספר: 151658	Number
תאריך: 9-09-2002	Date
הוקדם/נדחם: Ante/Post-dated	

אני, (שם, המבקש, מענו ולגבי גוף מאוגד - מקום התאגדותו)
I (Name and address of applicant, and in case of body corporate - place of incorporation)

BEN-GURION UNIVERSITY OF THE NEGEV
RESEARCH AND DEVELOPMENT AUTHORITY
P.O.Box 653
Beer-Sheva 84105

אוניברסיטת בן-גוריון בנגב
הרשות למחקר ופיתוח
ת.ד. 653
באר-שבע 84105

Inventors:
Israel Sekler
Michal Her,shfinkel
Zeev Silverman
Arie Moran

ממציאים:
ישראל סקלר
מיכל הרשפינקל
זאב סילברמן
אריה מורן

Owner, by virtue of the Law the Law הדין בעל אמצאה מכח
an invention the title of which is ששמה הוא
(Hebrew) (בעברית)

שיטות ותכשירים לטיפול ומניעה של מחלות לב וכלי דם

(English)

(באנגלית)

METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION
OF CARDIOVASCULAR DISEASES

hereby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי ינתן עליה פטנט

• בקשת חלוקה - Application of Division		• בקשת פטנט מוסף - Application for Patent Addition		דרישת דין קדימה Priority Claim		
מבקשת פטנט from Application No. Dated	מס' מיום	לבקשה/לפטנט to Patent/Appl. No. Dated	מס' מיום	מספר/סימן Number/Mark	תאריך Date	מדינת האגוד Convention Country
• יפוי כח: כללי/ מיוחד - רצוף/ בודד/ עוד יוגש P.O.A.: general/ individual - attached/to be filed later filed in case 126263 הוגש בענין						
המען למסירת מסמכים בישראל Address for Service in Israel LUZZATTO & LUZZATTO P.O. Box 5352 Beer-Sheva 84152		לוצאטו את לוצאטו 5352 באר שבע 84152				
התימת המבקש Signature of Applicant לוצאטו את לוצאטו ב"כ המבקשת LUZZATTO & LUZZATTO ATTORNEYS FOR APPLICANTS				2002	שנת of the year	ספטמבר September
				2		בחודש of
						היום This
						לשימוש הלשכה For Office Use

טופס זה, כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשה, הינו אישור להגשת הבקשה שפרטיה רשומים לעיל.
This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application the particulars of which are set out above.

Delete whatever is inapplicable

• מחק את המיותר

13382/mic/01

שיטות ותכשירים לטיפול ומוניעה של מחלות לב וכלי דם

METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION
OF CARDIOVASCULAR DISEASES

Field of the Invention

The present invention relates to a polypeptide (ZnT-1) involved in the regulation of L-type calcium channels and its use in the treatment and/or prevention of cardiovascular diseases.

Background of the Invention

All publications mentioned throughout this application are fully incorporated herein by reference, including all references cited therein.

According to the WHO, cardiovascular disease (CVD) was responsible for one third of global deaths in 1999. In developed countries, CVD is regarded as the major cause for morbidity and mortality. By 2010, CVD is estimated to be the leading cause of death in developing countries as well. Therefore, the search for more effective drugs to prevent and treat CVD is highly desirable.

Calcium channels play a key role in the physiology and pathophysiology of the cardiovascular system. Consequently, they are crucial pharmacological targets in the treatment of numerous cardiovascular diseases. For example, drugs aimed at reducing hypertension act by blocking the calcium influx pathway. However, a major drawback using these medicines is their relative high toxicity and lack of specificity.

The L-type calcium channels (LTCC), or sarcolemmal L (long lasting) channels, are typical calcium channels found in the myocardium and involved in calcium-induced calcium release. The LTCC is responsible for responding to the well-known Ca^{+2} channel blockers dihydropyridines. In fact, these channels are also known as dihydropyridine receptors, because of their high affinity to this class of Ca^{+2} channel blockers.

Zinc (Zn^{2+}) is among the most abundant trace elements in mammals. It is an essential micronutrient that has numerous structural and regulatory functions, including its interaction with zinc finger domains and acting as a cofactor in many enzymes [Vallee B.L. et al., *Physiol. Rev.* 73:79-118 1993]. Zinc ions also bind and specifically modulate the activity of many membrane receptors, transporters and channels [Choi D.W. et al. (1998) *Ann. Rev. Neurosci.* 21:347-75; Huang E.P. (1997) *Proc. Natl. Acad. Sci. USA* 94:13386-7]. The LTCC is one of the major routes of zinc entry in the brain [Sensi, S. L. et al. (1997) *J. Neurosci.* 17:9554-64]. In other cell types, such as glia or cardiomyocytes, the role of LTCC is even more prominent, being the only identifiable zinc influx pathway in these cells [Atar, D. et al. (1995) *J. Biol. Chem.* 270:2473-7]. The distribution of free zinc across the plasma membrane resembles that of calcium, since it has a large gradient, exceeding 5 to 6 orders of magnitude [Choi, D.W. and J.Y. Koh. (1998) *Annu. Rev. Neurosci.* 21:347-75]. In fact, opening of the calcium channels leads to a massive zinc influx [Atar (1995) *id ibid.*].

In the brain, the extracellular concentration of zinc is extremely high. As a result, massive release of synaptic zinc occurs during ischemia, which permeates into neurons, and most likely is the major factor in ischemic neuronal cell death [Choi D.W. et al. (1998) *id ibid.*; Choi D.W. et al. (1988) *Neuroscience* 24:67-79; Kim Y.H. et al. (1999) *Neuroscience* 89:175-82; Koh, J. Y. et al. (1996) *Science* 272: 1013-6]. The dynamic nature of zinc effects is further demonstrated in diverse pathophysiological syndromes including myocardial infarction, hepatic renal failure, and neoplasia. In such cases, striking changes occur in zinc plasma concentration and the rate of disappearance of these changes is considered a reliable prognostic marker [Vikbladh I. (1950) *Scand. J. Clin. Lab. Invest.* 2:143-148].

Sudden and de-regulated increase in intracellular zinc is highly cytotoxic. Therefore, maintenance of low intracellular zinc concentration is a very

important function. This maintenance is achieved either through systems that mediate extrusion of zinc against its high electrochemical gradient, or through systems that down-regulate zinc influx via the LTCC. Recent studies have linked a newly discovered family of putative zinc transporters, ZnT-1 through 4, to the maintenance of Zn^{2+} homeostasis and protection against zinc toxicity by a yet unidentified mechanism. In fact, the first putative mammalian zinc transporter (ZnT-1) was cloned through functional complementation of a mutant BHK cell line sensitive to extracellular zinc [Palmiter, R. D. and S. D. Findley (1995) *EMBO J.* 14:639-49]. ZnT-1 has a putative structure of six membrane spanning domains and it shares homology with a yeast zinc resistance gene and with a cobalt transporter [Palmiter (1995) *id ibid*]. So far, the functional mechanism of ZnT-1 remains unknown. In the examples hereby described, ZnT-1 down-regulates zinc influx through the LTCC, supporting a regulatory role rather than a direct transport activity.

Thus, it is an object of the invention to characterize ZnT-1 as a protein responsible for upholding Zn_i homeostasis. ZnT-1, originally described as a Zn^{2+} transporter, can function as a blocker of the LTCC and thereby regulate intracellular Zn^{2+} concentration. In addition, ZnT-1 can also be described as a regulator of Ca influx through the LTCC.

It is another object of the present invention to provide a pharmaceutical composition for the treatment of diseases that affect LTCC function, typically cardiovascular diseases, comprising ZnT-1 as the active agent.

These and other objects of the invention will become apparent as the description proceeds.

Summary of the Invention

In a first aspect, the present invention relates to a cellular L-type calcium channel (LTCC) blocker, namely ZnT-1, having the properties of: a modulator of LTCC function; and/or a modulator of intracellular zinc concentration; and/or a modulator of intracellular calcium concentration.

In a first embodiment, the LTCC blocker of the invention is active in any one of vascular, brain or heart cells.

In a second embodiment, the LTCC blocker of the invention, or ZnT-1, may be induced intracellularly upon exposing the cells to concentrations of from about 1 μ M to 1mM of zinc. Preferably, an induction is observed when the concentration of zinc is about 200 μ M.

In a second aspect, the present invention relates to a composition for blocking L-type calcium channels, comprising the LTCC blocker of the invention or ZnT-1, and optionally comprising pharmaceutically acceptable adjuvant, carrier, diluent or excipient, wherein said composition is for the treatment and/or prevention of cardiovascular diseases and related complications. Preferably, the composition of the invention is for the treatment and/or prevention of hypertension and stroke.

In a third aspect, the present invention provides a method of blocking zinc influx into a tissue, comprising infusing such tissue with a Zn-containing solution, and inducing the expression of the LTCC blocker or of ZnT-1.

In one embodiment, the tissue wherein zinc influx is to be blocked is derived from the circulatory system. Preferably, said tissue is any one of arteries, coronary arteries, brain arteries or cardiac tissue.

Lastly, the present invention provides a method of treating cardiovascular disorders in a patient in need of such treatment, comprising administering to said patient any one of the LTCC blocker of the invention, or ZnT-1, or the composition of the invention.

Brief Description of the Figures

Figure 1: Fura-2 fluorescence is dependent on Zn^{2+} concentration

The signal in this graph reflects changes in fluorescence signal measured at 340/380nm of excitation and 510nm emission, which is proportional to intracellular zinc levels, throughout a period of 600 seconds.

Figure 2: Zn^{2+} influx is inhibited by a L-type Ca channel blocker

HEK 293 cells were exposed to 400 μM zinc with or without 1 μM nimodipine. The LTCC blocker inhibited the influx of zinc into the cells. The signal in this graph reflects changes in fluorescence signal measured at 340/380nm of excitation and 510nm emission, which is proportional to intracellular zinc levels, throughout a period of 300 seconds.

Figure 3: Expression of ZnT-1 reduces zinc accumulation

a. Control and ZnT-1 transfected HEK 293 cells were exposed to 400 μM zinc, and the rate of zinc influx was monitored over time.

b. Expression of ZnT-1 was evaluated by Western Blot. The two bands reflect the presence of glycosylated and unglycosylated forms of ZnT-1. Endo-F (EF) was used to cleave the glycosyl residues of ZnT-1. Such treatment resulted in merging of the two bands into one, indicating that the presence of the two bands is indeed related to different glycosylation states of the protein.

Figure 4: ZnT-1 expression inhibits Zn^{2+} influx into cells

- a. Control and ZnT-1 transfected PC12 cells, expressing endogenous L-type Ca channels, were superfused with Ringer solution containing $400\mu\text{M}$ Zn^{2+} . The cells were then depolarized by high K^+ in the presence of zinc.
- b. Rate of zinc influx into the cells. After depolarization, the rate of zinc influx was three-fold slower in cells expressing ZnT-1 vs. control cells.

Figure 5: Co-expression of ZnT-1 and L-type Ca channels in HEK 293 cells reduces zinc influx

The graph shows zinc influx (measured by fluorescence) in cells transfected with L-type Ca channels (LTCC) alone (squares), cells transfected with LTCC in combination with ZnT-1 (diamonds), and control non-transfected cells (circles). Transfection with LTCC increased the zinc influx by about three-fold. Co-expression of LTCC and ZnT-1 caused reduction in the zinc influx to levels comparable to control.

Figure 6: ZnT-1 expression inhibits Ca^{2+} influx into cells

- a. Control and ZnT-1 transfected PC12 cells, expressing endogenous L-type Ca channels, were superfused with Ca-free Ringer solution. After addition of 1.8 mM calcium, the cells were depolarized by high K^+ for opening of the LTCC (arrows) and the levels of Ca start to decrease compared to control.
- b. Histogram of the rate of Ca influx into cells, control and ZnT-1 transfected.

Figure 7: ZnT-1 expression is induced by Zn in cultured brain astrocytes

- a. Astrocytes were treated with sub-lethal amounts (20 and $50\mu\text{M}$) of Zn^{2+} for 12 hours. Histogram shows the level of ZnT-1 expression in cells treated with 20 μM and 50 μM of Zn^{2+} or with EDTA. ZnT-1 expression is induced by Zn^{2+} in a dose-dependent manner.

b. Western Blot of ZnT-1 expression.

Figure 8: Zinc influx in cells induced to express ZnT-1 protein is reduced in a concentration-dependent manner

a. Astrocytes were pre-treated with zinc at the indicated concentrations, and subsequent rates of zinc influx were determined. The histogram represents the relative rate of zinc influx. Reduced zinc influx correlates with higher expression of ZnT-1.

b. Graph demonstrating the change in intracellular zinc following zinc application, in pre-treated and control cells.

Detailed Description of the Invention

For the purposes of clarity, the following terms are defined herein:

LTCC: L-type calcium channel, sarcolemmal L (long lasting) channel.

ZnT-1: Zinc transporter 1, LTCC blocker.

Cardiovascular disease (CVD): The term cardiovascular disease includes hypertension (high blood pressure), coronary heart disease (heart attack), cerebrovascular disease (stroke), peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease and cardiomyopathies.

ZnT-1 plays a key and novel physiological role in calcium homeostasis, being the first natural blocker of the LTCC. The clinical implications of these findings are significant since calcium influx through these channels is implicated in the pathogenesis of cardiovascular abnormalities such as high blood pressure at the vascular smooth muscle level, contractile and

electrophysiology abnormalities in the myocardial myocytes and specialized conduction cells at the cardiac cell level.

Thus, in a first aspect, the present invention relates to a cellular LTCC blocker, namely ZnT-1, having the properties of a modulator LTCC function, as well as of a modulator of intracellular zinc and/or calcium concentrations.

A LTCC modulator may enhance or inhibit the LTCC function. A modulator of intracellular zinc and/or calcium concentrations may regulate the influx or outflux of these ions from the cell, in order to maintain the appropriate concentrations. Thus, a modulator may trigger an increase or a decrease in the intracellular concentration of zinc and/or calcium.

As shown in the following Examples, cells expressing ZnT-1 can block both Zn^{2+} (Fig. 4) and Ca^{2+} (Fig. 6) influx into the cells in a similar fashion to nimodipine, a dihydropyridine that acts as a LTCC blocker.

The inventors have shown that ZnT-1 can lower intracellular zinc and furthermore, that ZnT-1 acts by downregulating ion influx through the LTCC. This is an original finding, never suggested in the existing prior art. These findings led the inventors to propose that ZnT-1 plays a significant role in the regulation of the LTCC, and in the mechanism for the lowering of intracellular zinc. Furthermore, the main known role of the LTCC is the regulation of calcium permeation and thereby the regulation of key homeostatic functions such as blood pressure. The results here presented thus indicate, for the first time, that ZnT-1 may be involved in regulating such processes. There are many examples for ion permeation pathways that have different selectivity for different ions. The results shown in Figure 6 are important, since they unambiguously demonstrate the role of ZnT-1 in the regulation of calcium permeation through this very important pathway. Moreover, under conditions of high extracellular concentration of Zn^{2+} , the

expression of ZnT-1 is induced. Thus, ZnT-1 seems to be the physiological regulator and blocker of LTCC function.

In a first embodiment, the LTCC blocker is active in vascular cells, cardiomyocytes, neurons and glia. This function is particularly relevant in astrocytes, embryonic kidney cells and pheochromocytoma cells.

In a second embodiment, the LTCC blocker of the invention, or ZnT-1, may be induced intracellularly upon exposing the cells to concentrations of from about 1 μ M to 1mM of zinc. Preferably, an induction is observed when the concentration of zinc is about 200 μ M.

In a second aspect, the invention relates to a composition for blocking L-type calcium channels, comprising a LTCC blocker or ZnT-1. ZnT-1 can regulate LTCC function, as well as modulate intracellular zinc and/or calcium concentrations.

Cells expressing LTCC in the presence of ZnT-1 have a rate of zinc influx about three fold slower than in its absence (Fig. 5).

In a first embodiment, the composition is for use in the treatment and/or prevention of cardiovascular diseases and related complications. Preferably the composition of the invention is for use in the treatment and/or prevention of hypertension and stroke.

Likely additives to the composition comprise pharmaceutically acceptable adjuvants, carriers, diluents or excipients. In addition, the composition may comprise additional pharmaceutically active components.

Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as

phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol and sorbitol; slat-forming counter-ions such a sodium; and/or non-ionic surfactants such as Tween, Plurionics™ or polyethylene glycol (PEG).

The pharmaceutical compositions of the invention can be prepared in dosage unit forms. The dosage forms may also include sustained release devices. The compositions may be prepared by any of the methods well known in the art of pharmacy. Such dosage forms encompass physiologically acceptable carriers that are inherently non-toxic and non-therapeutic. Examples of such carriers include ion exchangers, alumina, aluminum stearate, lecitin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and PEG. Carriers for topical or gel-based forms of the composition include polysaccharides such as sodium carboxymethylcellulose or methylcellulose, polyvinylpyrrolidone, polyacrylasts, polyoxyethylene-block polymers and PEG. For all administrations, conventional delivery forms are suitably used. Such forms include for example, microcapsules, nano-capsules, liposomes, plasters, inhalation forms, nose sprays, sublingual tablets, and sustained-release preparations.

The preparation of pharmaceutical compositions is well known in the art and has been described in many articles and textbooks, see e.g., Remington's Pharmaceutical Sciences, Gennaro A. R. ed., Mack Publishing Company, Easton, Pennsylvania, 1990, and especially pages 1521-1712 therein, fully incorporated herein by reference.

The magnitude of a therapeutic dose of the composition will of course vary with the group of patients (age, sex, etc.); with the stage of the disease, and with the route of administration. In any case, the attending physician will determine the therapeutic dose.

Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of an LTCC blocker or ZnT-1, or the pharmaceutical composition of the invention. Suitable routes of administration include oral, topical application or invasive administration techniques. The term "invasive" as used herein is to be taken to mean intra-cerebral, intraspinal, intramuscular, intravenous, intraperitoneal, subcutaneous, intra-articular, intrasynovial or intrathecal administration.

An "effective amount" of ZnT-1 or the composition of the invention to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required, to obtain the optimal therapeutic effect. Typically, the clinician will administer ZnT-1 until a dosage is reached that achieves the desired effect.

In another aspect, the invention comprises a method for blocking zinc influx into a tissue. In Example 8, the inventors show that astrocytes induced to express ZnT-1 have much reduced rates of zinc influx.

In a first embodiment, the method of the invention comprises infusing the tissue with a Zn-containing solution, and inducing the expression of the LTCC blocker or ZnT-1. Said tissue may be any one of vascular, brain or heart tissue. Preferably, said tissue is derived from the circulatory system. More preferably, said tissue is any one of arteries, coronary arteries, brain arteries or cardiac tissue.

In a second embodiment, the Zn-containing solution has a zinc concentration of from about $1\mu\text{M}$ to about 1mM , preferably $200\mu\text{M}$.

This method may be applicable in research, for topical treatment of tissues in need of increased ZnT-1 expression, or for systemic treatment of laboratory animals.

In yet another aspect, the invention relates to a method for treating and/or preventing cardiovascular disorders in a patient in need of such treatment.

In a first embodiment, the method of the invention comprises administering to the patient a LTCC blocker or ZnT-1, or a composition comprising the same, wherein said blocker is capable of modulating the intracellular concentration of zinc and/or calcium and of regulating LTCC function.

Preferably, said treatment is for a patient suffering from cardiovascular disease, in particular hypertension.

"Treatment" refers to therapeutic treatment. Those in need of treatment include those already with the disease or disorder, whether at clinical or pre-clinical stage.

Disclosed and described, it is to be understood that this invention is not limited to the particular examples, process steps, and materials disclosed herein as such process steps and materials may vary somewhat. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only and not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The following examples are representative of techniques employed by the inventors in carrying out aspects of the present invention. It should be appreciated that while these techniques are exemplary of preferred embodiments for the practice of the invention, those of skill in the art, in light of the present disclosure, will recognize that numerous modifications can be made without departing from the spirit and intended scope of the invention.

Examples

Experimental Procedures

General methods in Molecular Biology

A number of methods of the molecular biology art are not detailed herein, as they are well known to the person of skill in the art. Such methods include PCR cloning, expression of cDNAs, analysis of recombinant proteins or peptides, transformation of bacterial and yeast cells, transfection of mammalian cells, and the like. Textbooks describing such methods are, e.g., Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, ISBN: 0879693096, 1989; *Current Protocols in Molecular Biology*, by F. M. Ausubel, ISBN: 047150338X, John Wiley & Sons, Inc. 1988. These publications are incorporated herein in their entirety by reference. Furthermore, a number of immunological techniques are not in each instance described herein in detail, as they are well known to the person of skill in the art. See, e.g., *Current Protocols in Immunology*, Coligan *et al.* (eds), John Wiley & Sons. Inc., New York, NY.

Cell culture and transient transfections

PC12 and human embryonic kidney (HEK) 293 cells were grown in DMEM medium (Sigma) as described [Montrose Rafizadeh, C. *et al.* (1997) *J. Cell Physiol.* 170:299-308], and seeded on cover slides for 1-2 days prior to measurements.

HEK 293 cells were transiently transfected with 3 μ g of plasmid containing ZnT-1 (kindly provided by Dr. R. D. Palmiter, Howard Hughes Medical Institute, University of Washington, Seattle, WA) or vector alone, using the calcium precipitation method as described [Sekler, I. *et al.* (1995) *J Biol. Chem.* 270:11251-6]. Pheochromocytoma PC12 cells were co-transfected with ZnT-1 or EYFP (Clontech) for control, using the Fugene-6 reagent (Roche). Measurements were performed 36-48 hours following transfection.

Zn/Ringer superfusion:

Cells were superfused with a Ringer's solution containing: 120mM NaCl, 5mM KCl, 20mM glucose, 10 mM Hepes, 0.5 mM MgCl, 1.8 mM CaCl₂ at pH 7.4. For depolarization experiments aimed to fully activate the LTCC, 45mM NaCl were replaced with 45mM KCl. ZnSO₄ was added at the indicated concentration to this solution.

Fluorescence and imaging measurements:

Cells were incubated for 30 minutes with 5 μ M of the ratiometric dye Fura-2-AM (TEF Labs) in 0.1% BSA-sodium Ringer's solution. Fura-2-AM binds zinc with very high affinity. After incubation, the cells were washed in Ringer's solution and the cover glass mounted on a holder that allowed the perfusion of liquids into the cells. Signals resulting from Ca⁺² or Zn⁺² changes were distinguished by using the intracellular zinc chelator TPEN. Changes in intracellular cation concentration were monitored by a single cell imaging system, consisting of a Zeiss Axiovert 100, inverted microscope, Polychrome II monochromator (TILL Photonics) and a cooled CCD (PCO). The data was acquired and processed by Axon Imaging Workbench 2, Excel and KleidaGraph. Fura-2 was excited at 340nm and 380nm and the image obtained with a 510nm long-pass filter. The data was analyzed post acquisition, by selecting single cells (30-50) from the field of view and recording their activity.

Western Blot:

Western Blots were carried out in the classical method described in *Molecular Cloning – A laboratory manual* by Sambroock *et al.*, Cold Spring Harbor Laboratory Press, 2nd edition, 1989.

Example 1

Fura-2 fluorescence is dependent on Zn²⁺ concentration

To measure the accumulation of intracellular zinc, HEK 293 cells were superfused with Ca-free, zinc-containing Ringer solution, and the release of Fura-2 was evaluated. Fura-2 is a highly sensitive probe for changes in intracellular Zn^{2+} concentration. Addition of TPEN (tetrakis-(2-pyridylmethyl) ethylenediamine), a membrane permeable heavy metal chelator, lowered the fluorescence signal (Fig.1).

Example 2

Zn^{2+} influx is inhibited by a L-type Ca channel blocker

HEK 293 cells were exposed to 400 μM zinc with or without nimodipine, a dihydropyridine that acts as a L-type Ca channel (LTCC) blocker. The LTCC blocker inhibited the influx of zinc into the cells (Fig. 2).

Example 3

Expression of ZnT-1 reduces zinc accumulation

Control and ZnT-1 transfected HEK 293 cells were exposed to 400 μM zinc, and the rate of zinc influx was monitored over time (Fig. 3). The rate of zinc influx was attenuated in the presence of ZnT-1 to levels comparable to those seen in Figure 2, where the attenuation was caused by nimodipine. This result suggests that ZnT-1 functions in a manner similar to nimodipine, i.e., by blocking the LTCC.

Example 4

ZnT-1 expression inhibits Zn^{2+} influx into cells

PC12 cells are a very good model for studying the activity of the LTCC. Control and ZnT-1 transfected PC12 cells, expressing endogenous L-type Ca channels, were superfused with Ringer solution containing 400 μM Zn^{2+} (Fig. 4a). The cells were then depolarized by high K^+ in the presence of zinc. After depolarization, the rate of zinc influx was three-fold slower in cells expressing ZnT-1 vs. control cells (Fig. 4b).

Example 5

Co-expression of ZnT-1 and L-type Ca channels in HEK 293 cells reduces zinc influx.

Cells were transfected with L-type Ca channels (LTCC) alone or in combination with ZnT-1, and zinc influx was compared to control non-transfected cells. As depicted in Figure 5, transfection with LTCC increased the zinc influx about three-fold. Co-expression of LTCC and ZnT-1 caused reduction in the zinc influx to levels comparable to control (Fig. 5). This result indicates that ZnT-1 acts as an inhibitor of divalent cation influx mediated by LTCC.

Example 6

ZnT-1 expression inhibits Ca^{2+} influx into cells

Control and ZnT-1 transfected PC12 cells, expressing endogenous L-type Ca channels, were superfused with Ca-free Ringer solution. After addition of 1.8 mM calcium, the cells were depolarized by high K^+ for opening of the LTCC. The results shown in Figure 6 demonstrate that ZnT-1 inhibits the rate of Ca influx.

Example 7

ZnT-1 expression is induced by Zn in cultured brain astrocytes

In astrocytes, zinc influx is mainly mediated by the LTCC. Astrocytes were treated with sub-lethal amounts (20 and 50 μM) of Zn for 12 hours, and ZnT-1 expression evaluated by Western Blot (Fig. 7). The histogram shows the level of ZnT-1 expression in cells treated with different concentrations of Zn or with EDTA (Fig. 7). ZnT-1 expression is induced by Zn^{+2} in a dose-dependent manner.

Example 8

Zinc influx in cells induced to express ZnT-1 protein is reduced in a concentration-dependent manner

Astrocytes were pre-treated with 20, 50 or 100 μ M of zinc for 24 or 48 hours, and subsequent rates of zinc influx were determined. These different treatments were comparable, since the induction of ZnT-1 was stable. Relative rates of zinc influx are represented by a histogram (Fig. 8). Zinc treatment resulted in a reduction of zinc influx. The reduced zinc influx correlates with the increase in ZnT-1 expression, observed in Figure 7. These data strongly suggests that the expression level of ZnT-1 can be controlled by non-harmful substances such as zinc, which consequently result in the reduced activity of the LTCC. In sum, ZnT-1 can control the activity of LTCC.

Claims:

1. A cellular L-type calcium channel (LTCC) blocker, namely ZnT-1, wherein said blocker has the properties of:
 - (a) a modulator of LTCC function;
 - (b) a modulator of intracellular zinc concentration.
2. A cellular L-type calcium channel (LTCC) blocker, namely ZnT-1, wherein said blocker has the properties of:
 - (a) a modulator of LTCC function;
 - (b) a modulator of intracellular calcium concentration.
3. The LTCC blocker of any one of claims 1 or 2, which is active in any one of vascular, brain or heart cells.
4. The LTCC blocker of claim 1, induced intracellularly upon exposing the cells to concentrations of from about $1\mu\text{M}$ to 1mM of zinc
5. The LTCC blocker of claim 4, wherein the concentration of zinc is about $200\mu\text{M}$.
6. A composition for blocking L-type calcium channels, comprising the LTCC blocker of any one of claims 1 to 3, optionally comprising pharmaceutically acceptable adjuvant, carrier, diluent or excipient.
7. The composition of claim 6, for the treatment and/or prevention of cardiovascular diseases and related complications.
8. The composition of claim 7, for the treatment and/or prevention of hypertension and stroke.

9. A method of blocking zinc influx into a tissue, comprising infusing such tissue with a Zn-containing solution, and inducing the expression of the LTCC blocker of claim 1.
10. The method of claim 9, wherein said tissue is derived from the circulatory system.
11. The method of claim 10, wherein said tissue is any one of arteries, coronary arteries, brain arteries or cardiac tissue.
12. A method of treating cardiovascular disorders in a patient in need of such treatment, comprising administering to said patient any one of the LTCC blocker of any one of claims 1 or 2, ZnT-1, or the composition of any one of claims 6 to 8.

לוצאטו את לוצאטו
LUZZATTO & LUZZATTO

By: ע"י: 




Fig. 1





Fig. 2

a.



b.





Fig. 3

a.



b.




Fig. 4





Fig. 5



b.





Fig. 6

b.



a.




Fig. 7




Fig. 8

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.